WCN26-9166 Clinical outcomes and mortality predictors in Hepatitis B and C positive chronic liver disease patients undergoing maintenance hemodialysis in resource-limited settings: a prospective cohort study

Read full text Summarise with VIRAT
Authors: Yogesh K. Gaur
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Patients on maintenance hemodialysis (MHD) have higher prevalence and worse outcomes from chronic viral hepatitis (HBV/HCV). New direct-acting antivirals (DAAs) achieve high cure (SVR) rates for HCV including in CKD/ESRD, and oral nucleos(t)ide analogues (entecavir, tenofovir variants) form the backbone of HBV therapy; dosing and safety considerations differ in dialysis populations and must be followed. Recent guideline updates support use of many SOF-containing regimens and pangenotypic DAAs in ESRD, and recommend long-term entecavir or tenofovir for HBV with renal dose considerations.

Fields of Study & Subjects

Hepatitis C virus research Hepatitis B Virus Studies Liver Disease and Transplantation

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
106057–106057
Publication date
25 March 2026
Language
EN